UroGen Pharma (NASDAQ:URGN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Zacks.com reports. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The […]
UroGen Pharma (NASDAQ:URGN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product […]
UroGen Pharma (NASDAQ:URGN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates […]
UroGen Pharma (NASDAQ: URGN) has recently received a number of price target changes and ratings updates: 4/6/2022 – UroGen Pharma was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with […]
Equities research analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN – Get Rating) will announce $18.29 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for UroGen Pharma’s earnings, with the lowest sales estimate coming in at $15.46 million and the highest estimate coming in at $20.00 million. […]